@article{ea2cbd4f9da04c048fdba4461522202f,
title = "Fecal Volatile Metabolomics Predict Gram-Negative Late-Onset Sepsis in Preterm Infants: A Nationwide Case-Control Study",
abstract = "Early detection of late-onset sepsis (LOS) in preterm infants is crucial since timely treatment initiation is a key prognostic factor. We hypothesized that fecal volatile organic compounds (VOCs), reflecting microbiota composition and function, could serve as a non-invasive biomarker for preclinical pathogen-specific LOS detection. Fecal samples and clinical data of all preterm infants (≤30 weeks' gestation) admitted at nine neonatal intensive care units in the Netherlands and Belgium were collected daily. Samples from one to three days before LOS onset were analyzed by gas chromatography-ion mobility spectrometry (GC-IMS), a technique based on pattern recognition, and gas chromatography-time of flight-mass spectrometry (GC-TOF-MS), to identify unique metabolites. Fecal VOC profiles and metabolites from infants with LOS were compared with matched controls. Samples from 121 LOS infants and 121 matched controls were analyzed using GC-IMS, and from 34 LOS infants and 34 matched controls using GC-TOF-MS. Differences in fecal VOCs were most profound one and two days preceding Escherichia coli LOS (Area Under Curve; p-value: 0.73; p = 0.02, 0.83; p < 0.002, respectively) and two and three days before gram-negative LOS (0.81; p < 0.001, 0.85; p < 0.001, respectively). GC-TOF-MS identified pathogen-specific discriminative metabolites for LOS. This study underlines the potential for VOCs as a non-invasive preclinical diagnostic LOS biomarker. ",
keywords = "fecal biomarker, gas chromatography—ion mobility spectrometry, gas chromatography—time of flight—mass spectrometry, microbiota, neonatology, volatile organic compounds",
author = "Frerichs, {Nina M} and {El Manouni El Hassani}, Sofia and Nancy Deianova and {van Weissenbruch}, {Mirjam M} and {van Kaam}, {Anton H} and Vijlbrief, {Daniel C} and {van Goudoever}, {Johannes B} and Hulzebos, {Christian V} and Kramer, {Boris W} and d'Haens, {Esther J} and Veerle Cossey and {de Boode}, {Willem P} and {de Jonge}, {Wouter J} and Wicaksono, {Alfian N} and Covington, {James A} and Benninga, {Marc A} and {de Boer}, {Nanne K H} and Niemarkt, {Hendrik J} and {de Meij}, {Tim G J}",
note = "Funding Information: This work was supported by unrestricted grants from the Landelijke Vereniging van Crematoria (Dr. C.J. Vaillant Fonds); Zeldzame Ziekten Fonds and the European Union{\textquoteright}s Horizon 2020 research and innovation programme under the Marie Sk{\l}odowska-Curie grant agreement [grant number 814168]. None of the funding sources had any role in the design or conduct of the study. Funding Information: None of the co-authors received a honorarium, grant, or other form of payment for the production of this manuscript. Outside the submitted work, N.K.H.d.B. has served as a speaker for AbbVie and MSD. He has also served as a consultant and/or principal investigator for TEVA Pharma BV and Takeda. He has received a (unrestricted) research grant from Dr Falk, TEVA Pharma BV, MLDS and Takeda. The other authors have nothing to declare. Publisher Copyright: {\textcopyright} 2023 by the authors.",
year = "2023",
month = mar,
doi = "10.3390/microorganisms11030572",
language = "English",
volume = "11",
journal = "Microorganisms",
issn = "2076-2607",
publisher = "MDPI AG",
number = "3",
}